Photo: Public Domain / Wikimedia
Scientists at the University of Cardiff (UK) have discovered a mutation that contributes to the development of aggressive forms of malignant tumors, called castrate-resistant prostate cancer. About it reported in a press release on MedicaXpress.
It is known that patients with metastatic prostate cancer initially respond well to hormonal therapy which reduces the concentration of male sex hormones. At the same time, almost all patients in the end — about 2-3 years — develops castrate-resistant tumor, which can not be cured, despite the low level of the testosterone.
The researchers found that the mutation affecting the PIK3CA gene in prostate cells, contributes to the development of aggressive forms of tumors. PIK3CA encodes a protein that is a subunit of the enzyme phosphoinositide-3-kinase (PI3K), involved in growth, cell division and avoiding apoptosis (programmed cell death). Another gene PTEN is responsible for blocking the activity of PI3K, and mutations in it also cause the development of tumors.
Video, photo All from Russia.